Current status of cost utility analyses in total joint arthroplasty: a systematic review
- PMID: 25267271
- PMCID: PMC4385366
- DOI: 10.1007/s11999-014-3964-4
Current status of cost utility analyses in total joint arthroplasty: a systematic review
Abstract
Background: Total joint arthroplasty (TJA), although considered to be highly beneficial, is associated with substantial costs to the US healthcare system. Cost utility analysis has become an increasingly important means to objectively evaluate the value of a healthcare intervention from the perspective of both extending the quantity and improving the quality of life. Relatively little is known about the overall cost utility analysis evidence base in TJA.
Questions/purposes: The goals of this review were to (1) determine the cost utility of TJA interventions; (2) critically assess the quality of published US-based cost utility analyses using the Quality of Health Economic Studies instrument; and (3) determine what characteristics were common among studies receiving a high quality score.
Methods: A systematic review of the literature using the MEDLINE database was performed to compile findings and critically appraise US-based cost utility analysis studies for total hip and knee arthroplasty. Based on review of 676 identified articles, 23 studies were included. We used the Quality of Health Economic Studies instrument to assess study quality and one-sided Fisher's exact tests were applied to analyze the predictors of high-quality cost utility analysis.
Results: Very few studies compare the cost utility of TJA versus nonoperative intervention; however, the available evidence suggests that TJA can be cost-saving and is highly cost-effective compared with conservative management of end-stage arthritis. The majority of identified studies are focused on the cost utility of new implant technologies or comparisons among surgical alternatives. These studies suggest that the upfront costs associated with new technologies are cost-effective when there is a major reduction in a future cost. The quality of identified studies is quite high (Quality of Health Economic Studies Instrument score: mean 86.5; range, 63-100). National funding source (p = 0.095) and lifetime horizon for analysis (p = 0.07) correlate with high-quality evidence but do not reach significance.
Conclusions: Over the past 15 years, there has been a major increase in the volume of cost utility analyses published in total hip and knee arthroplasty. The quality of cost utility analyses published during that period is good. As increasing attention is paid to value in US health care, more attention should be paid to understanding the cost utility of TJA compared with nonoperative treatment modalities. Future studies may also look to incorporate patient willingness to pay.
Figures
Comment in
-
CORR Insights(®): current status of cost utility analyses in total joint arthroplasty: a systematic review.Clin Orthop Relat Res. 2015 May;473(5):1828-9. doi: 10.1007/s11999-014-4074-z. Epub 2014 Dec 3. Clin Orthop Relat Res. 2015. PMID: 25467788 Free PMC article. No abstract available.
Similar articles
-
Total hip replacement and surface replacement for the treatment of pain and disability resulting from end-stage arthritis of the hip (review of technology appraisal guidance 2 and 44): systematic review and economic evaluation.Health Technol Assess. 2015 Jan;19(10):1-668, vii-viii. doi: 10.3310/hta19100. Health Technol Assess. 2015. PMID: 25634033 Free PMC article.
-
Is Your Surgical Helmet System Compromising the Sterile Field? A Systematic Review of Contamination Risks and Preventive Measures in Total Joint Arthroplasty.Clin Orthop Relat Res. 2025 Jun 1;483(6):972-990. doi: 10.1097/CORR.0000000000003383. Epub 2025 Feb 5. Clin Orthop Relat Res. 2025. PMID: 39915114
-
Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.Health Technol Assess. 2006 Mar;10(8):1-142, iii-iv. doi: 10.3310/hta10080. Health Technol Assess. 2006. PMID: 16545207
-
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450. Health Technol Assess. 2007. PMID: 17999840
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
Cited by
-
Cost-effectiveness of Operative Versus Non-operative Management of Acute Achilles Tendon Ruptures.HSS J. 2020 Feb;16(1):39-45. doi: 10.1007/s11420-019-09684-0. Epub 2019 Jun 8. HSS J. 2020. PMID: 32015739 Free PMC article.
-
Cost and resource comparison analysis for THA in Switzerland and Austria.Int J Technol Assess Health Care. 2024 Oct 17;40(1):e36. doi: 10.1017/S0266462324000321. Int J Technol Assess Health Care. 2024. PMID: 39417297 Free PMC article.
-
Patterns of Depressive Symptoms Before and After Surgery for Osteoarthritis: A Descriptive Study.ACR Open Rheumatol. 2019 May 17;1(4):203-212. doi: 10.1002/acr2.1031. eCollection 2019 Jun. ACR Open Rheumatol. 2019. PMID: 31777796 Free PMC article.
-
Contingent Valuation Studies in Orthopaedic Surgery: A Health Economic Review.HSS J. 2018 Oct;14(3):314-321. doi: 10.1007/s11420-018-9610-z. Epub 2018 Apr 9. HSS J. 2018. PMID: 30258339 Free PMC article. Review.
-
Lessons Learned From the Comprehensive Care for Joint Replacement Model at an Academic Tertiary Center: The Good, the Bad, and the Ugly.J Arthroplasty. 2023 Jul;38(7 Suppl 2):S54-S62. doi: 10.1016/j.arth.2023.02.014. Epub 2023 Feb 11. J Arthroplasty. 2023. PMID: 36781061 Free PMC article. Review.
References
-
- Ballal RD, Botteman MF, Foley I, Stephens JM, Wilke CT, Joshi AV. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling. Curr Med Res Opin. 2008;24:753–768. doi: 10.1185/030079908X273048. - DOI - PubMed
-
- Botteman MF, Caprini J, Stephens JM, Nadipelli V, Bell CF, Pashos CL, Cohen AT. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States. Clin Ther. 2002;24:1960–1986; discussion 1938. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous